The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
The CEO of the drug company founded by Martin Shkreli on Thursday called Shkreli a "Pied Piper" who entranced investors and co-workers with his bold predictions of pharmaceutical success.
Retrophin CEO Stephen Aselage, during testimony at Shkreli's securities fraud trial, also called him a "brilliant intellect" and a "visionary."
Shkreli was a "Pied Piper ... he tells a story, sings a song," Aselage said.
But there were times, Aselage testified, when Shkreli was "not as credible as he could have been."
And when questioned by a prosecutor about why he remained at Retrophin after being kept in the dark about some things Shkreli was doing, Aselage said, "Yeah, I've asked myself that question a number of times."
Shkreli, 34, is charged in Brooklyn, New York, federal court with looting Retrophin of stock shares and cash to pay off investors in two hedge funds he ran, whom he is also accused of defrauding.
He has denied the charges, which are unrelated to his controversial hiking of the price of a drug more than 5,000 percent in 2015 while leading another company, Turing Pharmaceuticals.
Shkreli founded Retrophin in 2011, shortly after witnesses have said his hedge fund MSMB Capital effectively imploded by making a disastrous short-sale trade of stock in another drug company.
Witnesses have also said that when they tried to withdraw their investments in Shkreli's hedge funds after he said they were closing operations, he put them off for up to a year or more.
And, they testified, instead of giving them just cash, as requested, he gave them stock in Retrophin in addition to cash and had them sign settlement agreements promising not to sue Shkreli or Retrophin.
Prosecutors claim that Shkreli also created sham consulting agreements with some investors, who ended up being paid by Retrophin, to cover the money that he had lost in his hedge funds.
Bank records indicate that money investors had sent to Shkreli's MSMB hedge funds sometimes was sent directly into Retrophin accounts, without their knowledge.
Aselage testified Thursday that while he was serving on Retrophin's board there were no discussions about settlement agreements that Shkreli had signed with MSMB fund investors, nor did the board ever approve such deals.
He also said the board never approved consulting agreements used to pay MSMB investors in Retrophin stock.
Aselage testified that Shkreli contacted him "out of the blue" in 2012 and said he wanted Aselage to join his new company, Retrophin.
In a later call, Aselage said, Shkreli talked about his vision for "a great, new pharmaceutical company" and claimed that he was a "very successful investment manager."
However, prosecutors have claimed, Shkreli had already failed at running one hedge fund, Elea Capital, and had lost much if not all of the investor money he was handling at the MSMB funds.
Aselage said he agreed to join Retrophin as CEO. During his tenure in that post, he testified, he found Shkreli to be "bright" and capable of "knocking down walls."
But Aselage also came to feel Shkreli was really the one in charge of the company, while using Aselage as the face of the firm.
Aselage said that shortly after starting his job he found out the Retrophin did not have funding for operations, contrary to what Shkreli had told him.
At one point, Aselage said, Retrophin was "running on fumes."
He also testified that there was a concern about commingling of finances between the MSMB funds and Retrophin, and that it sometimes wasn't clear which employees were working for which firm.
Aselage later found out that Retrophin did not have insurance for its directors and officers to protect them personally if they were sued in connection with company activities.
"It's America," Aselage said. "In America, you can sue everybody ... it can wipe out someone's life savings."
Aselage said the lack of insurance, and the questions about who was actually in charge of Retrophin, left him in an "untenable position."
He testified that he wanted to resign as both CEO and a member of the company's board of directors.
But Shkreli and another Retrophin official convinced him to remain on the board.
On Wednesday, the former chairman of the board of Retrophin, Steven Richardson, testified about the events that led the board to fire Shkreli in 2014 and to re-install Aselage as CEO.
Richardson said that instead of curbing stock trading by Retrophin employees in what was an effective hedge fund within the company, Shkreli set up a commission-incentive structure for those workers, and then lied about it to Richardson.
Richardson also testified that Shkreli had himself been trading in Retrophin stock during periods when he was barred from doing so, and also was giving some new employees company shares without keeping track of the amounts. That latter practice risked diluting the value of shares held by existing Retrophin investors.
Richardson, who is gay and who was an investor in Shkreli's fund, said he believed Shkreli was saying such things because he believed Richardson wanted to hear them.